45347-82-8

Basic information

• Product Name: 3-AZETIDINOL
• Synonyms: 3-AZETIDINOL;AZETIDIN-3-OL;3-Hydroxyazetidine;(S)-methyl 2,2-dimethyl-1,3-dioxolane-4-carboxylate;Azetidin-3-ol, 3-Hydroxyazetane;3-AZETIDINOLHCL
• CAS NO: 45347-82-8
• Molecular Formula: C₃H₇NO
• Molecular Weight: 73.09
• Mol File: 45347-82-8.mol

Chemical Properties

• Boiling Point: 170.7 °C at 760 mmHg
• Flash Point: 120.4 °C
• Appearance: /
• Density: 1.142 g/cm³
• Vapor Pressure: 0.464mmHg at 25°C
• Refractive Index: 1.498
• Storage Temp.: 2-8°C(protect from light)
• PKA: 14.51±0.20(Predicted)
• CAS DataBase Reference: 3-AZETIDINOL(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AZETIDINOL(45347-82-8)
• EPA Substance Registry System: 3-AZETIDINOL(45347-82-8)

Safety Data

• Hazardous Substances Data: 45347-82-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
3-Azetidinol is used as a chiral building block for the synthesis of various pharmaceutical and agrochemical products. Its unique molecular structure allows for the creation of enantiomerically pure compounds, which is crucial for the development of effective and safe drugs and agrochemicals.
Used in Asymmetric Catalysis:
In the field of asymmetric catalysis, 3-Azetidinol serves as an efficient ligand, facilitating the transfer of chirality to target molecules. This application is vital for enhancing the selectivity and yield of chemical reactions, leading to the production of enantiomerically pure compounds with desired biological activities.
Used in Material Science:
3-Azetidinol has potential applications in the development of new materials due to its unique molecular structure. Its properties may contribute to the creation of innovative materials with specific characteristics for various applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3-Azetidinol is utilized for the design of bioactive compounds. Its ability to influence the chirality of molecules can lead to the discovery of new drugs with improved therapeutic effects and reduced side effects.

InChI:InChI=1/C3H7NO/c5-3-1-4-2-3/h3-5H,1-2H2

Upstream product

• 616-30-8 3-Amino-1,2-propanediol 
• 18621-17-5 1-(diphenylmethyl)-3-hydroxyazetidine 
• 141699-55-0 tert-butyl 3-hydroxyazetidine-1-carboxylate 
• 111043-42-6 N-benzyl-3-(trimethylsilyloxy)azetidine 

Downstream Products

• 128117-22-6 1-Benzyloxycarbonyl-3-hydroxyazetidine 
• 141699-55-0 tert-butyl 3-hydroxyazetidine-1-carboxylate 
• 392231-63-9 4-butoxy-benzenesulfonic acid 1-(4-butoxy-benzenesulfonyl)-azetidin-3-yl ester 
• 952742-87-9 1-(4-phenoxybenzyl)azetidin-3-ol 
• 952742-91-5 1-(2,4-dimethoxybenzyl)azetidin-3-ol 
• 937802-35-2 C₁₃H₁₅NO₄S 
• 937802-51-2 C₁₁H₁₄N₂O₄S 
• 118972-96-6 1-(3-hydroxyazetidin-1-yl)ethanone 
• 919357-22-5 1-(2,3,6-trifluoro-4-nitrophenyl)azetidin-3-ol 
• 1138041-12-9 1-{[4-(2-fluoropyridin-3-yl)-5-(phenylsulfonyl)thiophen-2-yl]methyl}azetidin-3-ol 
• 1196669-79-0 C₂₈H₂₉N₅O₂S 
• 857280-53-6 1-phenylazetidin-3-ol 
• 1246361-60-3 tert-butyl (2R)-1-(4'-(3-hydroxyazetidine-1-carbonyl)biphenyl-4-yl)-4-(3-(1-(3-methoxypropyl)-1H-indol-2-yl)piperidin-1-yl)-4-oxobutan-2-ylcarbamate 
• 1165800-49-6 C₂₆H₃₆N₄O₄ 

Relevant articles and documents

AZETIDINE CYCLIC UREAS

Provided are azetidine cyclic urea compounds that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

Continuous Hydrogenolysis of N-Diphenylmethyl Groups in a Micropacked-Bed Reactor

In recent years, with the advancements in continuous flow technology and the ever-increasing demand for green processes, continuous flow chemistry has become more and more widely adopted in the pharmaceutical industry. In this work, the continuous hydrogenolysis of N-diphenylmethylazetidin-3-ol to 3-azetidinol in micropacked bed reactors was demonstrated. The effects of different catalysts, solvent types, and the additives on the reaction in a micropacked-bed reactor were investigated. The results indicate that the reaction rate per reactor volume is increased by 100 times because of the larger interfacial area and shorter diffusion distance in micropacked reactors. To further study the long-term stability of the reaction system, the flow system was successfully operated for 240 h by adjusting the reaction temperature and liquid flow rate. The reaction kinetics model for the hydrogenation of N-diphenylmethylazetidin-3-ol in methanol was studied after the internal and external diffusion limitations were eliminated. In addition, the type of adsorption of the reactants on the catalyst and the rate-determining step of the reaction were investigated.

JAK INHIBITOR

The present invention discloses a series of JAK inhibitors, and particularly discloses a compound of formula (I) or a pharmaceutically acceptable salt thereof and the use thereof in preparation of drugs for treating diseases related to JAK.

CATALYST FOR SYNTHESIZING ETHYLENIMINE AS WELL AS PREPARATION METHOD AND APPLICATION THEREOF

The present invention relates to a catalyst for synthesizing ethylenimine as well as a preparation method and application thereof. The related catalyst comprises a carrier and metal ions loaded on the carrier; the carrier is a composite oxide comprising titanium, silicon and phosphorus elements; the metal ions are magnesium ions, iron ions and cesium ions; the molar ratio of the magnesium ions to the iron ions to the cesium ions is (1-10):1:0.1; the mass of all metal ions is 0.5-10 percent of that of the carrier. In the related preparation method, a catalyst precursor is roasted at the temperature of 350-650° C., so that the catalyst is obtained; the catalyst precursor is the mixture of the carrier, soluble salt of magnesium, soluble salt of iron and soluble salt of cesium. The present invention also provides the application of the catalyst to synthesis of the ethylenimine by using amino alcohol as the raw material. Compared with a common catalyst which has the requirement on the temperature of over 400° C., the catalyst of the present invention obviously reduces the reaction temperature. The prepared catalyst can catalyze the intramolecular dehydration reaction of the amino alcohol and has relatively excellent selectivity.

PYRIDINE DERIVATIVES AND APPLICATION OF ANTI-MACOBACTERIUM THEREOF

The present invention provides a series of pyridine derivatives and their preparation method and application thereof. The series of pyridine derivatives can be applied to treating mycobacterium-related diseases, especially to treatments of fatal mycobacterium-related diseases. The fatal diseases may be related to mycobacterium tuberculosis, mycobacterium bovis, mycobacterium avium, and mycobacterium marinum.

Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors

Phosphodiesterase 9A inhibitors have shown activity in preclinical models of cognition with potential application as novel therapies for treating Alzheimers disease. Our clinical candidate, PF-04447943 (2), demonstrated acceptable CNS permeability in rats with modest asymmetry between central and peripheral compartments (free brain/free plasma = 0.32; CSF/free plasma = 0.19) yet had physicochemical properties outside the range associated with traditional CNS drugs. To address the potential risk of restricted CNS penetration with 2 in human clinical trials, we sought to identify a preclinical candidate with no asymmetry in rat brain penetration and that could advance into development. Merging the medicinal chemistry strategies of structure-based design with parallel chemistry, a novel series of PDE9A inhibitors was identified that showed improved selectivity over PDE1C. Optimization afforded preclinical candidate 19 that demonstrated free brain/free plasma ≥1 in rat and reduced microsomal clearance along with the ability to increase cyclic guanosine monophosphosphate levels in rat CSF.

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes (I).

AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS

Compounds of formula (I): or pharmaceutically acceptable salts thereof, are agonists of GPR119 and are useful for the treatment of diabetes and as peripheral regulators of satiety, e.g. for the treatment of obesity and metabolic syndrome.

AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS

Compounds of formula (I) or pharmaceutically acceptable salts thereof, are agonists of GPR119 and are useful for the treatment of diabetes and as peripheral regulators of satiety, e.g. for the treatment of obesity and metabolic syndrome.

NEW ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS AND USES IN TREATMENTS OF OBESITY AND DIABETES MELLITUS - 087

The present invention relates to Acetyl Coenzyme A Carboxylase (ACC) inhibitors according to formula (I), or an enantiomer thereof, or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, E, L, Z and n are as defined herein, to processes for preparing such compounds, to pharmaceutical compositions containing them, to the use of such inhibitors and to methods for th eir therapeutic use, particularly in the treatments of obesity and diabetes mellitus.